Toward gene therapy in prosthesis loosening: Efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954

Journal of Gene Medicine

Volumn 7, Issue 11, 2005, Pages 1421-1428

  de Poorter, Jolanda J ^a   Tolboom, Tanja C A ^a   Rabelink, Martijn J W E ^a   Pieterman, Elsbet ^a   Hoeben, Rob C ^a   Nelissen, Rob G H H ^a   Huizinga, Tom W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell killing; Gene therapy; Hip; Interface; Prosthesis loosening

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; BACTERIAL ENZYME; BETA GALACTOSIDASE; CONTRAST MEDIUM; GENE PRODUCT; IOTROLAN; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NITROREDUCTASE; PRODRUG;

ARTICLE; CELL TYPE; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; INTERFACE CELL; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS LOOSENING; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; AGED; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; CONTRAST MEDIA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIP PROSTHESIS; HUMANS; NITROREDUCTASES; PRODRUGS; PROSTHESIS FAILURE; TRANSDUCTION, GENETIC; TRIIODOBENZOIC ACIDS;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HUMAN ADENOVIRUS TYPE 5;

EID: 27944473234     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.795     Document Type: Article

References (28)

1. Harris WH. Wear and periprosthetic osteolysis: the problem. Clin Orthop 2001; 393: 66-70.
2. Malchau H, Herberts P, Söderman P, Odén A. Prognosis of total hip replacement. Update and validation of results from the Swedish national hip arthroplasty registry 1979-1998. Proc 67th Ann Meeting of the American Academy of Orthopedic Surgeons, March 15-19, 2000; Orlando, USA.
3. Söderman P, Malchau H, Herberts P, Zugner R, Regner H, Garellick G. Outcome after total hip arthroplasty. II. Disease-specific follow-up and the Swedish National Total Hip Arthroplasty Register. Acta Orthop Scand 2001; 72: 113-119.
4. Strehle J, DelNotaro C, Orler R, Isler B. The outcome of revision hip arthroplasty in patients older than age 80 years: complications and social outcome of different risk groups. J Arthroplasty 2000; 15: 690-697.
5. Archibeck MJ, Jacobs JJ, Roebuck KA, Glant TT. The basic science of periprosthetic osteolysis. Instr Course Lect 2001; 50: 185-195.
6. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. Clin Orthop 2001; 393: 71-77.
7. Jones LC, Frondoza C, Hungerford DS. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res 1999; 48: 889-898.
8. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 2000; 60: 4179-4186.
9. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370.
10. Djeha AH, Thomson TA, Leung H, et al. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther 2001; 3: 233-240.
11. Chung-Faye G, Palmer D, Anderson D, et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662-2668.
12. Kormano M, Frey H. Toxicity of X-ray contrast media in cell cultures. Invest Radiol 1980; 15: 68-71.
13. Zhang H, Holt CM, Malik N, Shepherd L, Morcos SK. Effects of radiographic contrast media on proliferation and apoptosis of human vascular endothelial cells. Br J Radiol 2000; 73: 1034-1041.
14. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917.
15. van der Eb MM, Pietersen AM, Speetjens FM, et al. Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 2002; 9: 53-61.
16. Rea D, Havenga MJ, van Den AM, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244.
17. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.
18. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neil DA, Harris WH. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 1983; 65: 575-584.
19. Goossens PH, Huizinga TW. Adenoviral-mediated gene transfer to the synovial tissue. Clin Exp Rheumatol 2002; 20: 415-419.
20. Nita I, Ghivizzani SC, Galea-Lauri J, et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820-828.
21. Flaherty DM, Hinde SL, Monick MM, et al. Adenovirus vectors activate survival pathways in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287: L393-L401.
22. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370-380.
23. Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer 2003; 104: 104-112.
24. McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998; 5: 1061-1069.
25. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4: 40-48.
26. Weedon SJ, Green NK, McNeish IA, et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 2000; 86: 848-854.
27. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 2002; 62: 1425-1432.
28. Zimmermann T, Kunisch E, Pfeiffer R, et al. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture - primary culture cells markedly differ from fourth-passage cells. Arthritis Res 2001; 3: 72-76.